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Background: Pregnant women from developing countries are at high-risk of hepatitis E-associated high mortality
and constitute priority population for vaccination. So far, candidate vaccines have not been evaluated during
pregnancy. We evaluated our vaccine candidate, recombinant Neutralizing Epitope protein (rNEp) encapsulated
in liposomes, in pregnant mice.
Methods: A single dose (10 μg) of the formulation was administered intramuscularly on day 7 of pregnancy.
Titres of serum IgG antibodies to hepatitis E virus (IgG-anti-HEV), levels of cytokines and biochemical parameters
were determined. Spleens were harvested from pregnant and non-pregnant mice for immunophenotyping (flow
cytometry), cytokines (cytometric bead array, CBA) and gene expression of immune response genes (Taqman low
density array, TLDA). Histopathology studies of spleen, liver, kidneys, brain and muscle was carried out.
Results: The vaccine was well-tolerated during pregnancy as evidenced by histopathology and serum biochemical
parameters. Anti-HEV titres were significantly higher in the pregnant balb/c and C57BL/6 mice (3592 ± 802 and1016 ±
138 respectively, than in non-pregnant groups (634 ± 191 and 320 ± 55 respectively, p < 0.001 for both)
suggesting that the higher antibody response in pregnant mice was independent of the genetic makeup of
the host but immunogen-driven. Pups receiving vertically transferred antibodies developed lower anti-HEV
antibodies (p < 0.05) when immunized with the formulation after seronegativity than in the age-matched mice
without such antibodies. In non-pregnant mice, a Th1 response and discordance between splenic and serum
cytokines was evident while in pregnancy, a Th2 bias was observed irrespective of immunization. Increased
CD19 levels correlated with higher anti-HEV titres in pregnant mice.
Conclusion: The single dose of the vaccine was safe and highly immunogenic in pregnant mice. Degree and
type of immune response to vaccination during pregnancy is immunogen-driven. In-depth studies are needed
to understand the underlying immunologic mechanism(s). These encouraging results for a vaccine intended for
use in pregnant women should be confirmed in higher animals.* Correspondence: varankalle@yahoo.com
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Hepatitis E is a major public health problem in developing
countries and causes waterborne epidemics and sporadic
disease. Hepatitis E virus (HEV) has predilection for young
adults and causes high mortality (~20%) among pregnant
women, especially in the later trimesters [1]. Therefore,
pregnant women from endemic countries are considered
the ideal category for hepatitis E immunization. So far, 10
vaccine candidates including ours were shown to be effica-
cious in the preclinical trial in rhesus monkeys [2-11] and
two have undergone clinical trials [12,13]. However, except
for incidental immunization of pregnant women during a
clinical trial [14], none of these were evaluated during
pregnancy.
Small laboratory animals are not susceptible to HEV
and the virus does not grow to high titres in culture sys-
tems, eliminating possibility of traditional live/attenuated
vaccines. Development of recombinant vaccines remains
the best possible option, with most vaccine efforts fo-
cused on the Open Reading Frame-2 (ORF-2) capsid
protein. Of the two vaccine candidates completing
clinical trials, one was a 56 kDa protein produced in
insect cells which showed 95.5% efficacy after admin-
istration of three doses of 20 μg each at 0, 1 and 6
months [13]. The other was a bacterially expressed
protein HEV239, which showed 100% efficacy on ad-
ministration of three doses of 30 μg each at 0, 1 and 6
months [12]. This vaccine, Hecolin® is now commer-
cially available for use in China, but not globally, so
far. Subsequent use of this vaccine in the community
confirmed no adverse effects, protection for 4.5 years
and continued monitoring [15]. Cross-protective effi-
cacy was evident as the predominant strain in the area
was genotype-4 while the vaccine was derived from
genotype-1 virus.
HEV-ORF2 is highly conserved among HEV species
and encodes for a single structural protein (660aa, 88
kDa) that has been the target for vaccine development.
With the identification of a neutralization epitope (NE,
nt458-607, 150aa) within ORF-2 in 2004 [16], we evaluated
the utility of this smaller region in vaccine development. It
was subsequently shown that the ORF2-encoded protein
forms the capsid through its homodimeric subunits (do-
main E2 amino acids 394–606 and domain E2s amino acids
455–602) that is essential for HEV interaction with the host
cell. The neutralizing antibody recognition site of HEV was
mapped the on the E2s (I) domain [17].
Our initial studies in mice showed that the NE-based
DNA-prime-protein-boost (DPPB) approach was su-
perior to NE-DNA and ORF-2-DPPB formats [18].
ORF-2 and NE regions were further evaluated in rhe-
sus monkeys. Of these, liposome encapsulated DNA
and protein formulations as well as NE-DNA-DPPB
approach led to sterilizing immunity [8]. When onlyNE protein similarly encapsulated in liposomes and
administered to rhesus monkeys, similar protection
was recorded (Arankalle et al., manuscript in prepar-
ation). NE protein in combination with hepatitis B
surface antigen (HBsAg) was shown to be highly im-
munogenic to both the components in mice [19] and
rhesus monkeys [8].
In the absence of an effective treatment, protection of
pregnant women from hepatitis E-associated mortality
and morbidity by immunization is an effective alternative
approach. Immunization of women in child-bearing age,
though possible, is not practical and economically viable
in the resource-restricted countries needing hepatitis E
vaccine. As pregnant women routinely receive vaccines,
targeting this at-risk population appears to be feasible.
So far, hepatitis E vaccine has not been assessed during
pregnancy. As a first step, we evaluated our vaccine
candidate in pregnant mice and report a preliminary
analysis of the possible factors responsible for the ob-
served differences in the antibody titres with respect to
pregnancy.Results
Preparation of the immunogen
Figure 1a depicts purified recombinant neutralizing epi-
tope protein (rNEp) as a single band of ~23 kDa with
strong immunoreactivity in western blot (Figure 1b).
Endotoxin levels were less than 10 EU/mg of protein.ELISA
Antibody titres in pregnant/non-pregnant mice
At one week post-immunization, no seroconversion was
noted in either mice group whereas 100% seroconver-
sion was observed 2 weeks post-dose in both pregnant
and non-pregnant balb/c mice. Geometric mean titres
(GMT) in the pregnant mice (3592 ± 802) were signifi-
cantly higher (p < 0.001) than in the non-pregnant mice
(634 ± 191.3) (Figure 2a). In C57BL/6 mice, 100% sero-
conversion was observed 2 weeks post-dose in both
pregnant and non-pregnant mice. Anti-HEV titres were
significantly higher (p < 0.001) in the pregnant mice
(1016 ± 138) than in the non-pregnant mice (320 ± 55)
(Figure 2b).Antibody titres in immunized-mother-mice and pups
IgG anti-HEV antibodies persisted in the mothers till
11 weeks and in the corresponding pups till 9 weeks
after birth (Figure 3a). At 4 weeks, anti-HEV titres
were higher in the pups than in the mothers (p < 0.05)
and declined subsequently. During 5–12 weeks, anti-
body titres were higher in the mothers (p < 0.05)
Figure 1 Immunogen preparation (a) Depicts purified NE protein of expected size (23 kDa) on 12% SDS-PAGE and (b) Immunoreactivity of the
protein with IgG anti-HEV positive human serum in western blot.
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anti-HEV antibodies to active immunization with the candidate
vaccine
At 9 weeks after birth, the pups scored IgG anti-HEV
negative. When a single dose of the same formulation was
administered to these pups at 13 weeks, anti-HEV titers
were significantly lower (168 ± 50) than the age matched
mice (580 ± 118) receiving the same dose (p < 0.05,
Figure 3b)
Immunophenotyping of splenocytes
We first assessed the surface markers for immune cell
types important in Th1 /Th2 and humoral responses i.e.,
T helper cells (Figure 4a), B cells (Figure 4b), dendritic cells
(Figure 4c) and macrophages (Figure 4d). In non-pregnant
mice, a significant rise was noted in the percentage of
CD11c+ cells at 24 hrs post-dose (p < 0.05).
CD3+CD4+ cells increased with pregnancy duration
(p < 0.05). Though statistically insignificant, the num-
bers of CD11b+ cells were higher in the pregnant mice.
Following immunization, CD19+ cells increased signifi-
cantly at 2 weeks post-dose in the pregnant mice when
compared to the pregnant controls or non-pregnant-
immunized groups (p < 0.001 for both).
The levels of co-stimulatory/activation markers i.e.,
CD11c+CD80+, CD11c+CD86+, CD11c+MHC-II+, CD19+
MHCII+, CD11b+MHCII+, CD11c+D69+, CD19+CD69+,
CD11b+CD69+, CD4+CD69+ were independent of preg-
nancy and immunization (p > 0.05, data not shown).
Though higher number of CD19+CD69+ cells was re-
corded in the pregnant mice at 24 hrs post-dose, the
difference was statistically insignificant.
Estimation of cytokines in NE-stimulated splenocyte
cultures
Comparisons of NE-specific Th1/Th2 response showed
that IL-2 levels remained comparable between non-
pregnant and pregnant groups at 24 hrs and 2 weeks(Figure 5a). At 2 weeks post-immunization, IFN-γ levels
increased in both non-pregnant (8fold) and pregnant
(4fold) mice, when compared to the respective, 24 hrs-
post-immunization categories (p < 0.05, Figure 5b). IFN-
γ levels at 2 weeks post immunization were significantly
lower in the immunized pregnant mice compared to
non-pregnant mice (p < 0.05). An increase was noted for
IL-4 in non-pregnant (2fold) and pregnant (7.5fold) mice
at 2 weeks compared to 24 hrs post dose (p < 0.05,
Figure 5c). IL-5 levels were unchanged in non-pregnant
mice at both time points, while in the immunized preg-
nant mice at 2 weeks, a 2.3 fold increase compared to 24
hrs was noted.(p < 0.05) (Figure 5d). Levels of IL-4 and
IL-5 in the pregnant immunized group at 2 weeks were
significantly higher than that of the non-pregnant mice
at 2 weeks. (p < 0.05)
Estimation of serum cytokines
Th1 cytokines
None of the Th1 cytokines (IL-2/IFN-γ/IL-12p40/IL-
p70) were detected in the unimmunized and immunized
non-pregnant mice. IL-2 levels (22.17 ± 0.21 pg/ml) were
higher during early-pregnancy, declining to 4.7 ± 0.2 pg/ml
in the later phase (p < 0.001). Immunization did not alter
IL-2 levels. The increase in IL-12p40 levels at 2 weeks post-
dose (28.9 ± 2.2 pg/ml) was reflection of pregnancy status
(19.5 ± 0.40 pg/ml). During early pregnancy, immunization
led to significant induction of IL-12p70 (30.16 ± 2.4 pg/ml
to 103 ± 7.2 pg/ml, p < 0.001). The levels were comparable
at 2 weeks (40.8 ± 3.1, 36.4 ± 1.4 pg/ml respectively). IFN-γ
was undetectable during healthy pregnancy, elevated at 24
hrs (56.6 ± 5.7 pg/ml, p < 0.001) and reduced (6.2 ± 1.1
pg/ml, p < 0.001) at 2 weeks post-dose (Table 1).
Th2 cytokines
Of the 3 Th2 cytokines estimated (IL-4/IL-6/IL-10), IL-4
was undetectable in all the mice groups. Non-pregnant
mice exhibited increased IL-6 levels at 24 hrs (20.9 ± 1.9
Figure 2 IgG Anti-HEV titres in (a) pregnant and non-pregnant balb/
c mice at 1 and 2 weeks post dose, (b) pregnant and non-pregnant
C57BL/6 mice at 2 weeks post dose. **indicates significant difference;
p values < 0.001 (t-test).
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weeks post-dose (p < 0.001). Immunization during
pregnancy led to an increase in IL-6 levels (12.9 ± 0.74
to 45.9 ± 1.4 pg/ml, p < 0.005) in the early phase and
declined to 25 ± 0.5 pg/ml (p < 0.005) at 2 weeks post-
dose. IL6 levels were higher at 2 weeks post-dose than
in the respective unimmunized category (p < 0.05). IL-10
levels declined in immunized non-pregnant mice at 24 hrs
(4 ± 1 pg/ml) as compared to the controls (12 ± 2.3 pg/ml,
p < 0.05), returning to normal levels at 2 weeks (10.2 ± 0.1
pg/ml). Pregnancy led to increased IL-10 levels in the
late phase (25.6 ± 2.5 pg/ml) that was not altered by
immunization (23 ± 2.5 pg/m, p > 0.05) (Table 1).Th1/ Th2 ratio in pregnancy
In the absence of detectable IFN-γ and IL-4 levels, we
compared IL-2/IL-10 ratios. During later pregnancy,
levels of the Th1 cytokine (IL-2) decreased from 22.2 to
4.7 while the Th2 cytokine (IL-10) increased from 15.4
to 25.6, the Th1/Th2 ratio decreasing from 1.44 to 0.18,
suggestive of Th2 bias. Following immunization, the
Th1/Th2 ratio dropped to 0.11 (Table 2).mRNA expression levels of the immune response genes
The heatmap (Figure 6) depicts that the pregnant immu-
nized group at 2 weeks was distinctly different, healthy
pregnancy and non-pregnant immunized group at 2 weeks
clustered together whereas non-pregnant and pregnant
groups at 24 hours were different. In the non-pregnant
immunized group, except for the downregulation of CD3
at 24 hrs (2.7fold), all the other T-Cell surface molecule
genes were within the normal range at both time points.
During normal pregnancy, only CTLA was downregulated
(2.1fold) that was similar (3.4fold) at 24 hours-post-dose
and normal at 2 weeks. All the B-cell surface marker genes
were normally expressed in the non-pregnant mice at both
time points post-immunization. Pregnancy did not alter
expression of these genes. However, an elevation was seen
at 2 weeks-post-dose in CD19 (2.8) and CD40Ig (3.3)
levels, normally expressed at 24 hrs. The other cell-
surface-markers were within the normal range in the im-
munized non-pregnant and pregnant unimmunized mice
groups. In the immunized pregnant group, upregulation of
CD80 (2.1fold) and MHCII (2.4 fold), and downregulation
(2.1fold) of B2m were noted.
Of the Th1 cytokine genes investigated, in the non-
pregnant immunized mice, IFN-γ was up and downregu-
lated respectively at 24 hrs and 2 weeks post-dose (2.8,
3.1fold) while IL-2 remained downregulated at both time
points (7.6, 2.5fold). As compared to 2-4fold downregula-
tion of all the genes in early pregnancy, except for IL-15
(2.3fold), all the other genes were at normal levels post-
immunization. As against normal expression of TBX-21/
IL-15/IL-12α and downregulation of IL-12β (4fold), IL-2
(4.3fold) and IFN-γ (3fold) during late pregnancy, IL-12α
and IL-15 levels were normal and IL-12β (2.6fold), IL-2
(3.23fold), IFN-γ (2.9fold) and Tbx21 (2.3fold) were down-
regulated at 2 weeks post-dose.
In non-pregnant mice, both the Th2 cytokines (IL-4/
IL-10) were downregulated at 24 hours (2.7fold and
2.3fold) and 2 weeks (5.7fold and 3.4fold). At 8 days and 2
weeks of normal pregnancy respectively, unaltered and
4.2fold lower IL4 gene expression respectively was noted
while IL-10 was downregulated throughout (2.7fold and
5.9fold). On immunization, IL-4 and IL-10 expression was
lower at 8 days (3.7fold and 2.7fold) returning to normal
levels at 2 weeks.
Figure 3 IgG anti-HEV titres in (a) balb/c mothers and pups at different intervals, Arrow indicates time for immunization of pups (b) in balb/c
mice with or without vertically transferred antibodies , 2 weeks post dose. *indicates significant difference , p values < 0.05 (t-test).
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levels with the expression of respective genes in the spleen
and induction of these cytokines by rNEp-stimulated cul-
tures of splenocytes isolated at the same time point. In the
non-pregnant mice, at both points post-immunization,
serum cytokines correlated with spleen gene expres-
sion. When the splenocyte cultures at 2 weeks post-
immunization were stimulated with rNEp, both IL-4
(2fold) and IFN-γ (6.4fold) increased suggesting Th1
bias. In the pregnant, immunized mice, discordance
between serum cytokines and gene expression was
noted. In non-immunized pregnant mice, a correlation
was seen for IL-4 and IFN- γ. At 24 hours post-
immunization both non-pregnant and pregnant mice
behaved similarly; at 2 weeks, a Th2 bias was evident.
Histopathology and biochemical markers
No abnormalities were recorded when tissue pathology
(spleen, liver, kidneys, brain and muscles) of the immu-
nized, pregnant/non-pregnant mice and respective non-immunized controls were compared (Figure 7). Levels of
SGPT (4-22U/L), SGOT (74-125U/L), urea (40-80 mg/dl)
and creatinine (0.2-0.6 mg/dl) were within the normal
range for all the groups.
Discussion
Our vaccine candidate was earlier evaluated in mice (1
μg, 3 doses 1 month apart) [19] and monkeys (20 μg, 2
doses 1 month apart) [8] and shown to be highly effi-
cacious in the rhesus model. As we were planning to
give a single dose and pregnancy may hinder antibody
response, a higher dose of 10 μg dose was chosen. The
results clearly show that even a single dose of the vaccine
could induce 100% seroconversion and high anti-HEV
titres in both balb/c and C57BL/6 mice, irrespective of
pregnancy.
The vaccine was well-tolerated by the pregnant mice
immunized during early second para as no obvious ad-
verse symptoms or abnormal biochemical parameters/
tissue pathology were noted (Figure 7). Higher anti-HEV
Figure 4 Surface staining of splenocytes of mice groups at different time points. (a) CD3+CD4+ T cells (b) CD19+ B cells (c) CD11c+ dendritic
cells (d) CD11b+ macrophages. Values represent as mean percent of gated splenocytes ± S.D. NPR = non – pregnant immunized mice, PI = pregnant
immunized mice and PNI = pregnant non-immunized mice. Values in parentheses represent means of absolute counts in spleen. *within the
parentheses denotes multiplied by 106. *indicates p value < 0.05 (ANOVA).
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for both, Figure 2a, 2b) clearly indicate that the enhanced
titres during pregnancy did not reflect genetic makeup of
the host, but, driven by the formulation used. In this regard,
a report from China is noteworthy [14]. A review of the re-
cords of the large phase 3 clinical trial of the vaccine [12],
now sold as Hecolin® in China identified that 37/31,791
pregnant women were inadvertently given one (n = 22),
two (n = 14) or three (n = 1) doses of the vaccine. Adverse
events were comparable in pregnant and non-pregnant
women and the vaccine was safe for the mother and fetus.
Of note, in the only woman who received 3 doses of the
vaccine, antibody level increased from undetectable to 34.7
Wu/mL, which was higher than that of 80% of subjects
who received three doses of the vaccine. Overall, results in
humans [14] and two mice strains (present study) seem to
be comparable and worth pursuing further. Importantly,
the 2 vaccines represent 458-607 nt (150aa, this study) and
368-606 nt (239aa, Hecolin®) regions of ORF2.
The other important point to note is that higher
antibody response during pregnancy is not a universalphenomenon led by pregnancy-associated Th2-bias
but appears to be immunogen-driven. MF59 adjuvanted
Focetria H1N1pnd09 influenza vaccine elicited lower anti-
body titres in pregnant women when compared to the
non-pregnant women [20] whereas though statistically
insignificant, rabies vaccine induced higher antibody ti-
tres in the pregnant women [21]. The observed higher
anti-HEV titres in pregnant mice are encouraging for a
vaccine intended for use in pregnant women.
To understand the association of increased anti-HEV
titres during pregnancy, we determined (1) proportion of
T helper (CD4+) and antigen presentation cells (CD11c+,
CD11b+ and CD19+) in the splenocytes (2) antigen-
specific cytokine induction in the spleen and (3) serum
Th1/Th2 cytokine levels. A significant rise in CD11c+ den-
dritic cells in the non-pregnant mice (Figure 4c) suggests
involvement of dendritic cells in antigen presentation with
the single dose of rNEp-liposome formulation. Similar re-
sults were obtained when 2 doses of an HA-based vaccine
with Matrix-M were administered to mice [22]. It is in-
teresting to note that when a single dose of ovalbumin
Figure 5 Cytokine levels in pg/ml ± S.E (standard error) in NE-restimulated splenocyte supernatants at 72 hrs of (a) IL-2 (b) IFN-γ (c) IL-4 and
(d) IL-5. Values represent mean cytokine measurements from different mice belonging to one group NPR = non–pregnant immunized mice,
PI = pregnant immunized mice and PNI = pregnant non-immunized mice. *indicates p value <0.05(ANOVA).
Table 1 Estimation of serum Th1/Th2 cytokine levels
Groups Time point Cytokine levels pg/ml (Std.error)
IL-2 IFN-γ IL-12p40 IL-12 p70 IL-6 IL-10
Naiive 0.2(0) 0.2(0) 0.2(0) 0.2(0) 0.2(0) 12.0 (2.3)
NPR* 24 hrs 0.2(0) 0.2(0) 0.2(0) 0.2(0) 20.9 (1.92) 4.1 (1.1)
NPR 2 wks 0.2(0) 0.2(0) 0.2(0) 0.2(0) 8.3 (0.2) 10.2 ( 0.1)
PI** 24 hrs 19.4 (1.1) 56.6 (5.8) 0.2(0) 103 (7.2) 45.9 (1.4) 11.3 (1.5)
PI 2wks 2.7 (0.2) 6.2 (1.1) 28.9 (2.2) 36.4 (1.4) 25.5 (0.5) 23 (2.5)
PNI*** Day8 22.2 (0.2) 0.2(0) 0.2(0) 30.2 (2.4) 12.9 (0.7) 15.4 (0.4)
PNI Day18 4.7 (0.2) 0.2(0) 19.6 (0.4) 40.8 (3.1) 0.2(0) 25.6 (2.5)
p-values
naiive vs NPR 24 hrs N.S N.S N.S N.S <0.001 N.S
naiive vs NPR 2wks N.S N.S N.S N.S <0.001 N.S
NPR 24 hrs vs NPR 2wks N.S N.S N.S N.S <0.05 <0.05
PI 24 hrs vs PI 2wks <0.001 <0.001 <0.001 <0.05 N.S <0.05
PNI day8 vs PNI day18 <0.001 N.S <0.05 N.S <0.05 <0.05
PI 24 hrs vs PNI day8 N.S <0.001 N.S <0.001 <0.05 N.S
PI 2wks vs PNI day18 N.S <0.05 N.S N.S <0.001 N.S
NPR 24 hrs vs PI 24 hrs <0.001 N.S <0.001 <0.001 <0.05 <0.001
NPR 2wks vs PI 2wks <0.001 <0.001 <0.001 <0.001 <0.001 <0.05
*indicates non-pregnant immunized group, **PI = pregnant immunized group, ***PNI = pregnant non-immunized mice group.
N.S. = not significant, p > 0.05. (ANOVA test).
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Table 2 Th1/Th2 ratios in pregnant mice






PNI* 8 (early) 22.2 15.4 1.44
PNI 18 (late) 4.7 25.6 0.18
PI** 8 (24 hrs post dose) 19.4 11.3 1.71
PI 18 (2 weeks post dose) 2.7 23 0.11
*is pregnant non-immunized group, **is pregnant immunized group.
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number of DCs in bone marrow did not increase after
immunization, enhanced actin-dependent active endo-
cytosis was noted confirming the role of DCs [23].
Overall, similar to adjuvants like Matrix M [22], MPL-A
[24], CpG and LTK63 [25] and cationic liposome DDA
[23], rNEp-liposome acts through DCs. In contrast,Figure 6 Heatmap of immune response genes in different mice groups.
NPR = non-pregnant immunized group, PI = pregnant immunized
and PNI = pregnant unimmunized group. Green color indicates
downregulation, black represents normal expression and red indicates
upregulation of genes.differential activation of immune cells during pregnancy
(Figure 4a, b) was evident by an increased number of
CD19+ and CD4+ splenocytes in the pregnant mice that
correlated with higher anti-HEV titres. With attenuated
Salmonella vaccine, immunization of non-pregnant mice
led to rise in CD8 cells while the numbers in pregnant
mice remained unchanged [26].
NE-stimulated splenocytes from the immunized, non-
pregnant mice favored Th1 response (Figure 5b). Thus,
irrespective of a single dose (10 μg, this study) or 3 doses
of 1 μg each [19], the vaccine formulation led to Th1 re-
sponse. However, the pregnant mice generated a distinct
Th2 cytokine response (Figure 5c, d). The levels of IFN-γ
were significantly lower in the pregnant immunized mice
(Figure 5b). These observations reveal that similar to Sal-
monella vaccine, pregnancy modulated Th1 response to
the vaccine to a Th2 response. A single dose of 1, 5, 10 μg
of VLPs of 56 kDa swine HEV-ORF2 with alum induced
a Th1 response when splenocytes were stimulated with
the same antigen three weeks post intra-muscular
immunization [27]. Taken together, these results sug-
gest that irrespective of size of the protein or adjuvant,
HEV-ORF2 induces Th1 response in mice and pregnancy
dictates a distinct shift to Th2-bias.
Assessment of systemic Th1/Th2 responses (Table 1)
revealed absence of Th1 cytokines (IFN-γ, IL-2 and IL-12)
and low levels of Th2 cytokines (IL-6 and IL-10) in non-
pregnant mice. This cytokine profile is in accordance with
the results obtained with a single dose of trivalent influ-
enza vaccine with MF59, alum and other adjuvants [28].
Several studies have noted discordance between Th1/Th2
profiles in spleen and sera in non-pregnant mice [19,29].
During pregnancy, the maternal immune response is
altered to accommodate fetus and pregnancy is believed
to be associated with a systemic shift towards a Th2
cytokine profile [30]. However, this hypothesis is being
debated [31]. With the advancement of pregnancy, the
Th1/Th2 (IL-2/IL-10) ratios decreased in both unimmu-
nized (1.46 to 0.18) and immunized (1.71 to 0.12) preg-
nant categories, suggestive of Th2 bias (Table 2).
Gene expression profile differentiated immunized preg-
nant mice at 2 weeks from the other groups suggesting
vaccine-induced alterations (Figure 6). A concomitant in-
crease in the CD19 gene expression and surface expres-
sion of this marker in the pregnant immunized mice is
noteworthy. An upregulation of CD40Ig, CD80 and
MHCII genes in the pregnant immunized groups suggest
their role in generating an enhanced immune response to
the formulation. When we compared serum IL-2/IL-4/
IFN-γ cytokines and expression of corresponding genes in
the spleen (Table 3), a complete correlation was observed
in non-pregnant immunized mice and unimmunized
pregnant mice (except IL-2). However, discordance was
noted in the pregnant immunized group that is under
Table 3 Cytokine levels in the sera / supernatants of stimulated-splenocytes and expression of corresponding genes in




Serum cytokines (pg/ml) Gene expression spleen (fold change) Splenocytes (rNEp-stimulated , pg/ml)
IL-2 IL-4 IFN-γ IL-2 IL-4 IFN-γ IL-2 IL-4 IFN-γ
NPR 24 hrs* UD UD UD 7.6D 2.7D 2.8U 5 5 4.7
NPR 2 weeks UD UD UD 2.5D 5.7D 3.1D 5 10 30
PI 24 hrs** 19.4 UD 56.6 0.7 3.7D 0.9 5 4.5 4.8
PI 2 weeks 2.7 UD 6.2 3.2D 0.9 2.9D 4.5 20 10
PNI day 8*** 22.2 UD UD 2.6D 2.2D 3.2D 4.8 4.5 4.2
PNI day 18 4.7 UD UD 4.3D 4.2D 3D 5 4.5 4.8
*indicates non-pregnant immunized mice, **indicates pregnant immunized mice, ***indicates pregnant unimmunized mice. UD = undetectable, D = downregulation,
U = upregulation.
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As postulated by Keene, probable role of ribonome, an
infrastructure between the genome and proteome that
may regulate early response genes such as cytokines
cannot be ruled out [32].
We further showed that the vertically transferred IgG
anti-HEV antibodies could be detected in the pups till 9Figure 7 Histopathology findings of (a) muscle (b) kidney (c) brain (d) live
(P), 24 hrs post dose. CN represents unimmunized non-pregnant mice contweeks after birth (Figure 3a). An earlier report described
passive transfer of antibodies after immunizing Swiss
albino mice prior to mating with three doses of vaccine
formulations [33]. Studies have shown that antibody
responses to active immunization with different vaccines
vary in the presence of vertically transferred antibodies.
In humans, vaccines for hepatitis A [34], measles [35]r and (e) spleen in immunized non-pregnant (N) and pregnant mice
rols and CP denotes unimmunized pregnant mice controls.
Joshi and Arankalle Virology Journal  (2015) 12:70 Page 10 of 12and rotavirus [36] led to impaired antibody response
while no effect was recorded for hepatitis B [37] and
Polio [38] vaccines. Reduction in antibody titres for
rotavirus in both mice [39] and humans [36] is note-
worthy. We showed for the first time that immunization
of mice with vertically transferred IgG anti-HEV anti-
bodies resulted in lower antibody response than that
observed in age-matched controls without such antibodies
(Figure 3b). Importantly, at the time of immunization, the
mice were IgG anti-HEV negative. Though hepatitis E vac-
cine is not envisaged to be administered to the infants
from endemic countries, as the disease is seen mainly in
young adults, our results will have implications in deciding
vaccination age in such countries.
Considering the need for this vaccine in pregnant
women, the data generated in mice is very encouraging
and must be extended to higher animals. It is also import-
ant to evaluate if the higher titres are adjuvant dependent.
The results will help in specifically formulating vaccines
that will be beneficial for pregnant women, the vulnerable
group with high mortality.Conclusion
Our study shows that the vaccine candidate is well-
tolerated during pregnancy in a murine model and induces
high anti-HEV titres. This could probably be associated
with the increased CD19+ cells along with Th2 cytokines in
the spleen and a Th2 bias observed in sera at 2 weeks
post immunization. The preliminary data suggests dif-




The recombinant NE protein (rNEp) was cloned,
expressed and purified as described previously [18,19].
Immunogen preparation was similar except increase in
rNEp to 10 μg. Endotoxin levels were measured using
LAL chromogenic endotoxin quantitation kit (Thermo-
scientific, U.S.A). The cationic liposomes were prepared
using cholesterol, hydrogenated soy phosphatidyl choline
(HSPC) and stearyl amine. The antigen: liposome mass
ratio was 1: 200, w/w). The mixture was lyophilized and
reconstituted overnight in sterile PBS before use.
Studies in mice
The study was approved by the Institutional Animal Ethical
Committee and carried out according to the guidelines.
Immunization schedule and specimen collection
Eight weeks old pregnant and age-matched non-
pregnant balb/c (n = 8 for both groups) and C57BL/6
(8 non-pregnant, 5 pregnant) mice were immunized
intramuscularly with a single dose (10 μg) of the vaccine
candidate. Pregnant mice were administered the dose on
day 7 of pregnancy i.e., early second para. Blood samples
were collected by retro-orbital bleeding prior to and one
and ~ two weeks post-dose and sera was stored at −20°C/-
80°C till tested for anti-HEV IgG titres and cytokines. In
C57BL/6 mice, only antibody response was studied.d for organ harvesting.
Joshi and Arankalle Virology Journal  (2015) 12:70 Page 11 of 12Both non-pregnant (NPR) and pregnant immunized
(PI) mice were sacrificed at (1) 24 hours-post-dose and
(2) ~ two weeks-post dose. As controls, unimmunized
pregnant mice (PNI) were sacrificed at the same time
points. Unimmunized non-pregnant (naiive) mice served
as controls (Figure 8). The spleens were harvested and
used for surface staining, Cytometric Bead Array (CBA)
and Taqman Low Density Array (TLDA).
Vertical transfer of anti-HEV antibodies and response to
active immunization
To assess the persistence of vertically transferred IgG
anti-HEV antibodies, 8 pregnant, immunized mice were
kept for delivery and a total of 41 pups were born. The
pups were bled at regular intervals for 14 weeks. To
determine the effect of passively transferred antibodies
on immune response to active immunization, in a separ-
ate experiment, set of pups (n = 10) born to different
vaccinated mice were immunized at the age of 13 weeks.
Age matched mice born to non-immunized, anti-HEV
negative mothers (n = 10) were used as controls.
ELISA and serum cytokines
Anti-HEV positivity and titres were determined by rORF-2
based ELISA [18]. Serum cytokines were measured by
milliplex mouse cytokine kit (Millipore, Germany).
Samples from the same group were pooled and run in
triplicates.
Immunophenotyping of splenocytes
Single cell suspension of splenocytes was prepared as
per standard protocol in RPMI by teasing the spleen
followed by R.B.C lysis (BD Pharmlyse) and passing
through a 70 μ cell strainer (BD Biosciences) .The anti-
mouse antibodies used for staining were: T-cell markers:
FITC-CD3 (clone17A2)/PE-CD4 (GK1.5)/B cell marker:
APC-Cy7-CD19 (ID3)/macrophage marker: FITC-CD11b
(M1/70)/Dendritic cell marker: APC-CD11c (HL3) (BD
Pharminogen, U.S.A). Splenocyte cluster was gated
and a minimum of 20000 events were acquired for
every sample on BD FACS ARIA II flow cytometer.
Samples were analyzed using BD FACS DIVA software.
(BD Biosciences, U.S.A).
Cytometric Bead array (CBA)
To assess the Th1/Th2 cytokines in the supernatants of
splenocytes, CBA kit (BD Biosciences, U.S.A) was used
as described previously [40]. Briefly, 1 million cells were
seeded in RPMI supplemented with 2% FBS per well and
were stimulated with 1 μg of rNEp. Cell supernatants
were collected after 72 hrs and stored in −80°C till tested.
Concanavalin A stimulated (2.5 μg/well) and unstimulated
cells served as positive and negative controls respectively.Values represent mean cytokine measurements of individ-
ual mice of a group ± Standard error (SE).
Taqman Low density Array (TLDA)
Total RNA extraction and gene expression analysis was
done from frozen spleen samples as described previously
[41]. The TLDA card was loaded on to the 7900HT Fast
Real Time PCR system (Applied Biosystems). 500 ng of
RNA was used for cDNA synthesis cDNAs from spleens
of naive mice were used as calibrators.18 s gene was
kept as endogenous control. Relative quantification (RQ)
values below 0.5 were considered as downregulation and
values greater than 2 were considered as upregulation.
Histopathology and serum biochemical markers
Spleen, liver, kidney, brain and muscles at the site of in-
jection were harvested, stored in 10% buffered formalin
and processed for histopathology as per standard proto-
cols. Serum liver transaminases (SGPT and SGOT), urea
and creatinine levels were determined for all the mice
groups using Dimension RXL Max machine (Siemens,
Germany).
Statistical analysis
Student’s t test and ANOVA were performed using SPSS
11 software. Non-responders in each group were included
for analysis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SJ was involved in planning the experiments, performed all the experiments
and analyses and wrote the manuscript. VA planned and supervised the
study and helped in writing the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
The authors would like to thank the Director, National Institute of Virology
for timely help and support. Special thanks to Mr. Shirish Vaidya for computer
assistance during manuscript preparation. Ms. Shivali Joshi would like to thank
Indian Council of Medical Research (ICMR) for the fellowship and project funding.
Author details
1National Institute of Virology, 130/1, Sus Road, Pashan, Pune 411021, India.
2ICMR consultant, National Institute of Virology, 130/1, Sus Road, Pashan,
Pune 411021, India.
Received: 2 December 2014 Accepted: 22 April 2015
References
1. Teshale EH, Hu DJ, Holmberg SD. The two faces of hepatitis E virus. Clin
Infect Dis. 2010;51:328–34.
2. Zhou YH, Purcell RH, Emerson SU. Truncated ORF2 protein contains the
most immunogenic site on ORF2: antibody responses to non-vaccine
sequences following challenge of vaccinated and non-vaccinated macaques
with hepatitis E virus. Vaccine. 2005;23:3157–65.
3. Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, et al. A bacterially
expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and
protectivity on primates. Vaccine. 2005;23:2893–901.
Joshi and Arankalle Virology Journal  (2015) 12:70 Page 12 of 124. Kamili S, Spelbring J, Carson D, Krawczynski K. Protective efficacy of hepatitis
E virus DNA vaccine administered by gene gun in the cynomolgus
macaque model of infection. J Infect Dis. 2004;189:258–64.
5. Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of
cynomolgus monkeys against HEV infection by oral administration of
recombinant hepatitis E virus-like particles. Vaccine. 2004;22:370–7.
6. Ma H, Song X, Harrison TJ, Li R, Huang G, Zhang H, et al. Immunogenicity
and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by
experimental infection of primates. Arch Virol. 2009;154:1641–8.
7. Huang WJ, Zhang HY, Harrison TJ, Lan HY, Huang GY, Wang YC. Immunogenicity
and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from
hepatitis E virus genotype 4. Arch Virol. 2009;154:481–8.
8. Arankalle VA, Lole KS, Deshmukh TM, Srivastava S, Shaligram US. Challenge
studies in Rhesus monkeys immunized with candidate hepatitis E vaccines:
DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes.
Vaccine. 2009;27:1032–9.
9. Zhang M, Emerson SU, Nguyen H, Engle R, Govindarajan S, Blackwelder WC,
et al. Recombinant vaccine against hepatitis E: duration of protective
immunity in rhesus macaques. Vaccine. 2002;20:3285–91.
10. Im SW, Zhang JZ, Zhuang H, Che XY, Zhu WF, Xu GM, et al. A bacterially
expressed peptide prevents experimental infection of primates by the
hepatitis E virus. Vaccine. 2001;19:3726–32.
11. Purdy MA, McCaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley
DW. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus
macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol.
1993;41:90–4.
12. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and
safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale,
randomised, double-blind placebo-controlled, phase 3 trial. Lancet.
2010;376:895–902.
13. Shrestha MP, Scott RM, Joshi DM, Mammen Jr MP, Thapa GB, Thapa N, et al.
Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med.
2007;356:895–903.
14. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J, et al. Safety of the
hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology.
2012;55:2038.
15. Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, et al. Long-term
efficacy of a hepatitis E vaccine. N Engl J Med. 2015;372:914–22.
16. Zhou YH, Purcell RH, Emerson SU. An ELISA for putative neutralizing
antibodies to Hepatitis E virus detects antibodies to genotypes 1, 2, 3
and 4. Vaccine. 2004;22:2578–85.
17. Li S, Tang X, Seetharaman J, Yang C, Gu Y, Zhang J, et al. Dimerization of
hepatitis E virus capsid protein E2s domain is essential for virus-host
interaction. PLoS Pathog. 2009;5(8), e1000537.
18. Deshmukh TM, Lole KS, Tripathy AS, Arankalle VA. Immunogenicity of
candidate hepatitis E virus DNA vaccine expressing complete and truncated
ORF2 in mice. Vaccine. 2007;25:4350–60.
19. Shrivastava S, Lole KS, Tripathy AS, Shaligram US, Arankalle VA. Development of
candidate combination vaccine for hepatitis E and hepatitis B: a liposome
encapsulation approach. Vaccine. 2009;27:6582–8.
20. Bischoff AL, Følsgaard NV, Carson CG, Stokholm J, Pedersen L, Holmberg M,
et al. Altered response to A (H1N1) pnd09 vaccination in pregnant women:
a single blinded randomized controlled trial. Plos one. 2013;8(4), e56700.
21. Sudarshan MK, Madhusudana SN, Mahendra BJ, Ashwathnarayana DH,
Jayakumary M, Gangaboriah. Post exposure rabies prophylaxis with Purified
Verocell Rabies Vaccine: a study of immune response in pregnant women
and their matched controls. Indian J Public Health. 1999;43:76–8.
22. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L.
Immune enhancing properties of the novel Matrix-M™ adjuvant leads to
potentiated immune responses to an influenza vaccine in mice. Vaccine.
2013;31:1725–33.
23. Korsholm KS, Agger EM, Foged C, Christensen D, Dietrich J, Andersen CS,
et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium
liposomes. Immunology. 2007;121:216–26.
24. De Becker G, Moulin V, Pajak B, Bruck C, Francotte M, Thiriart C, et al. The
adjuvant monophosphoryl lipid A increases the function of antigen-presenting
cells. IntImmunol. 2000;12:807–15.
25. Hannesdottir SG, Olafsdottir TA, Giudice GD, Jonsdottir I. Adjuvants LT-K63
and CpG enhance the activation of dendritic cells in neonatal mice. Scand J
Immunol. 2008;68:469–75.26. Negi VD, Nagarajan AG, Chakravortty D. A safe vaccine (DV-STM-07) against
Salmonella infection prevents abortion and confers protective immunity to
the pregnant and new born mice. PLoS One. 2010;5(2), e9139.
27. Song YJ, Park WJ, Lee SK, Lee JB, Park SY, Song CS, et al. Induction of
antibody and interferon-γ production in mice immunized with virus-like particles
of swine hepatitis E virus. J Vet Sci. 2014;15:575–8.
28. Valensi JP, Carlson JR, Van Nest GA. Systemic cytokine profiles in BALB/c
mice immunized with trivalent influenza vaccine containing MF59 oil
emulsion and other advanced adjuvants. Jimmunol. 1994;153:4029–39.
29. Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based
and whole-virus inactivated candidate vaccines against chikungunya virus.
Vaccine. 2012;30:6142–9.
30. Athanassakis I, Iconomidou B. Cytokine production in the serum and spleen
of mice from day 6 to 14 of gestation: cytokines/placenta/spleen/serum.
Dev Immunol. 1996;4:247–55.
31. Orsi NM, Gopichandran N, Ekbote UV, Walker JJ. Murine serum cytokines
throughout the estrous cycle, pregnancy and post partum period. Anim
Reprod Sci. 2006;96:54–65.
32. Keene JD. Ribonucleoprotein infrastructure regulating the flow of genetic
information between the genome and the proteome. Proc Natl AcadSci.
2001;98:7018–24.
33. Jiménez de Oya N, Alonso-Padilla J, Blázquez AB, Escribano-Romero E,
Escribano JM, Saiz JC. Maternal transfer of antibodies to the offspring after
mice immunization with insect larvae-derived recombinant hepatitis E
virus ORF-2 proteins. Virus Res. 2011;158:28–32.
34. Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J, et al.
Immunogenicity of an inactivated hepatitis A vaccine in infants and young
children. Pediatr Infect Dis J. 2007;26:116–22.
35. Njie-Jobe J, Nyamweya S, Miles DJ, Van Der Sande M, Zaman S, Touray E,
et al. Immunological impact of an additional early measles vaccine in
Gambian children: responses to a boost at 3 years. Vaccine. 2012;30:2543–50.
36. Appaiahgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari
N, et al. Transplacental rotavirus IgG interferes with immune response to live
oral rotavirus vaccine ORV-116E in Indian infants. Vaccine. 2014;32:651–6.
37. Wang Z, Zhang S, Luo C, Wu Q, Liu Q, Zhou YH, et al. Transplacentally
acquired maternal antibody against hepatitis B surface antigen in infants
and its influence on the response to hepatitis B vaccine. PLoS One.
2011;6(9), e25130.
38. Bavdekar SB, Naik S, Nadkarni SS, Kamat JR, Deshpande JM, Vaswani LK.
Effect of passively transferred anti-poliovirus antibodies on seroconversion.
Indian J Pediatr. 1999;66:45–8.
39. Johansson E, Istrate C, Charpilienne A, Cohen J, Hinkula J, Poncet D, et al.
Amount of maternal rotavirus-specific antibodies influence the outcome of
rotavirus vaccination of newborn mice with virus-like particles. Vaccine.
2008;26:778–85.
40. Saravanabalaji S, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle
VA. Viral load, antibody titres and recombinant open reading frame 2
protein-induced Th1/Th2 cytokines and cellular immune responses in self-limiting
and fulminant hepatitis E. Intervirology. 2009;52:78–85.
41. Patil DR, Hundekar SL, Arankalle VA. Expression profile of immune response
genes during acute myopathy induced by chikungunya virus in a mouse
model. Microbes Infect. 2012;14:457–69.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
